Ask AI

Capsule Summaries

Share

Program Content

Activities

  • SAVE Trial
    SAVE: Phase I/II Study of Oral Revumenib Plus Decitabine/Cedazuridine and Venetoclax in Cohort of Patients with Newly Diagnosed AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2025

  • ASC2ESCALATE
    ASC2ESCALATE: Asciminib in Patients With Chronic-Phase CML After 1 Prior TKI
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2025

  • VICEROY
    VICEROY: Venetoclax + Azacitidine + Gilteritinib in Patients With ND FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2025

  • PARADIGM
    PARADIGM: Randomized Phase II Trial of Azacitidine + Venetoclax vs Conventional Intensive Chemotherapy for Fit Patients With Newly Diagnosed AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2025

  • FASCINATION
    Phase II FASCINATION: 3-Yr Update of Asciminib + Conventional BCR::ABL1 Inhibitors in Newly Diagnosed CML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2025

  • KOMET 007
    KOMET-007: Phase Ib Study of Ziftomenib + Venetoclax/Azacitidine in Newly Diagnosed NPM1-Mutated Acute Myeloid Leukemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner